Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Materials
i2O Therapeutics has launched with $4 million in seed funding from Sanofi Ventures and the JDRF T1D Fund to develop ionic liquid–based drug delivery technology. Using ionic liquid technology from the lab of Harvard University bioengineer Samir Mitragotri, i2O hopes to create oral forms of drugs that now must be delivered via needle. Its first target is GLP-1analogs, which help balance glucose levels to treat diabetes.
This article has been sent to the following recipient: